Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.

Literature DB >> 33152104

Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.

Preetesh Jain¹, Loretta Nastoupil¹, Jason Westin¹, Hun Ju Lee¹, Lucy Navsaria¹, Raphael E Steiner¹, Sairah Ahmed¹, Omar Moghrabi¹, Onyeka Oriabure¹, Wendy Chen¹, Maria Badillo¹, Christopher R Flowers¹, Michael L Wang¹.

Abstract

Entities: Chemical Disease Species

Keywords: BTK inhibitor; Mantle cell lymphoma (MCL); brexucabtagene autoleucel; chimeric antigen receptor therapy; ibrutinib; non-Hodgkin lymphoma; venetoclax

Year: 2020 PMID： 33152104 DOI： 10.1111/bjh.17197

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

Review 1. From antibodies to living drugs: Quo vadis cancer immunotherapy?

Authors: Árpád Szöőr; János Szöllősi; György Vereb
Journal: Biol Futur Date: 2021-02-01

Review 2. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.

Authors: Dimitrios L Wagner; Ulrike Koehl; Markus Chmielewski; Christoph Scheid; Renata Stripecke
Journal: Front Immunol Date: 2022-06-17 Impact factor: 8.786

Review 3. MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.

Authors: Chiara Cioccarelli; Barbara Molon
Journal: Clin Exp Immunol Date: 2022-06-11 Impact factor: 5.732

Review 4. Improving and Maintaining Responses in Pediatric B-Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor-T Cell Therapy.

Authors: Rahul Arya; David M Barrett; Stephan A Grupp; Jan Joseph Melenhorst
Journal: Cancer J Date: 2021 Mar-Apr 01 Impact factor: 2.074

10. Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada.

Authors: Graeme Ball; Christopher Lemieux; David Cameron; Matthew D Seftel
Journal: Curr Oncol Date: 2022-03-17 Impact factor: 3.677

Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.

Review 1. From antibodies to living drugs: Quo vadis cancer immunotherapy?

Review 2. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.

Review 3. MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.

Review 4. Improving and Maintaining Responses in Pediatric B-Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor-T Cell Therapy.

Review 5. T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy.

Review 6. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.

Review 7. Biological Therapies in the Treatment of Cancer-Update and New Directions.

Review 8. Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer.

Review 9. The potential of CAR T cell therapy for prostate cancer.

10. Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada.